EG427 Announces New Preclinical Results from Multiple Studies of EG110A in Neurogenic Detrusor Overactivity (NDO) and Overactive Bladder (OAB) EG427 Announces New Preclinical Results from Multiple Studies of EG110A in Neurogenic Detrusor Overactivity (NDO) and Overactive Bladder (OAB) In a non-clinical pharmacology study in an OAB model,...

EG 427 announces final Series A closing, achieving €18 million in total funds raised Paris, France, 13 July, 2023 – EG 427, a biotechnology company leading the development of pinpoint DNA medicine solutions, announces today the final closing of a Series A financing. EG 427 raised an...